Skip to main content

Advertisement

SpringerLink
Log in

Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies

  • Original Article
  • Published:
Archives of Osteoporosis Aims and scope Submit manuscript

Abstract

Summary

Denosumab is a newly approved treatment for osteoporosis in China. However, the clinical safety and advantages of denosumab have not been much established. The current study evaluates the real-world safety of denosumab versus zoledronic acid in treating cancer-free adults aged 50 years or older with osteoporosis to provide clinical settings guidelines.

Purpose

A head-to-head comparison of the safety profiles between denosumab (60 mg subcutaneously every 6 months) and zoledronic acid (5 mg, intravenously yearly) was performed in cancer-free adults aged 50 years or older with osteoporosis.

Methods

MEDLINE, EMBASE, and Cochrane Library databases were searched for cohort studies comparing the safety of denosumab and zoledronic acid in cancer-free adults aged 50 years or older with osteoporosis till December 2021. The outcomes included the risk of fracture and other severe adverse events. Based on the Cochrane Handbook for Systematic Reviews of Interventions 5.0.2, we identified the eligible studies.

Results

Three cohort studies having 38,845 cancer-free adults aged 50 years or older were included in the study. The results showed that denosumab was not superior to zoledronic acid in reducing fracture risk [RR (95% CI): 1.05 (0.90, 1.23), P = 0.52]. However, denosumab had a low risk of composite cardiovascular disease [RR (95% CI): 0.82 (0.70, 0.96), P = 0.01]. There were no significant differences between the hazards of serious infection, and total adverse events (P > 0.05).

Conclusion

The present meta-analysis demonstrated that for cancer-free adults aged 50 years or older with osteoporosis, denosumab was as safe as zoledronic acid for the risk of drug-induced fractures. However, denosumab had a lower incidence of composite cardiovascular disease, and may be a better option for the population with cardiovascular disease. Nonetheless, due to limitations like a short-term follow-up, gender, and incomplete types of adverse effects, more randomized controlled trials (RCTs) are required to further verify this conclusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377(9773):1276–1287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wang L, Yu W, Yin X, Cui L, Tang S, Jiang N, Cui L, Zhao N, Lin Q, Chen L, Lin H, Jin X, Dong Z, Ren Z, Hou Z, Zhang Y, Zhong J, Cai S, Liu Y, Meng R, Deng Y, Ding X, Ma J, Xie Z, Shen L, Wu W, Zhang M, Ying Q, Zeng Y, Dong J, Cummings SR, Li Z, Xia W (2021) Prevalence of osteoporosis and fracture in China: the China Osteoporosis Prevalence Study. JAMA Netw Open 4(8):e2121106

    Article  PubMed  PubMed Central  Google Scholar 

  3. Coughlan T, Dockery F (2014) Osteoporosis and fracture risk in older people. Clin Med (Lond) 14(2):187–191

    Article  PubMed  Google Scholar 

  4. Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, Jia J, Liu L, Liu G, Wang J, Zhan S, Song C (2020) Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study. PLoS Med 17(8):e1003180

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hou XL, Liu JY, Fan XH, Zhang N, Cao GL, Guo ZB, Zhang YY, Yu YH, Tian YQ, Sun XX, Tian FM (2022) Secular trends of incidence and hospitalization cost of hip fracture in Tangshan. China Osteoporos Int 33(1):89–96

    Article  PubMed  Google Scholar 

  6. Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ (2015) Projection of osteoporosis-related fractures and costs in China: 2010–2050. Osteoporos Int 26(7):1929–1937

    Article  CAS  PubMed  Google Scholar 

  7. Hertz K, Santy-Tomlinson J (eds) (2018) Fragility fracture nursing: holistic care and management of the orthogeriatric patient [Internet]. Springer, Cham (CH)

    Google Scholar 

  8. Curtis EM, Moon RJ, Harvey NC, Cooper C (2017) The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone 104:29–38

    Article  PubMed  PubMed Central  Google Scholar 

  9. Furlan G, Caduff-Janosa P, Sottosanti L, Cappello E, Valdiserra G, Tuccori M (2020) Drug safety in geriatric patients: current status and proposed way forward. Drug Saf 43(9):853–866

    Article  PubMed  Google Scholar 

  10. Cosman F (2020) Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture. Endocr Pract 26(7):777–786

    Article  PubMed  Google Scholar 

  11. Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22(1):21–26

    Article  CAS  PubMed  Google Scholar 

  12. Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC (2017) Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int 28(12):3289–3300

    Article  CAS  PubMed  Google Scholar 

  13. Dhillon S (2016) Zoledronic acid (Reclast ®, Aclasta ®): a review in osteoporosis. Drugs 76(17):1683–1697

    Article  CAS  PubMed  Google Scholar 

  14. Nayak S, Greenspan SL (2022) Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis. Osteoporos Int 33(1):229–238

    Article  CAS  PubMed  Google Scholar 

  15. Takada J, Iba K, Yamamoto O, Dohke T, Saito A, Yamamura M, Takebayashi T, Akatsuka T, Yamashita T (2021) Early adverse events after the first administration of zoledronic acid in Japanese patients with osteoporosis. J Bone Miner Metab 39(5):903–910

    Article  CAS  PubMed  Google Scholar 

  16. You R, Mori T, Ke L, Wan Y, Zhang Y, Luo F, Feng D, Yu G, Liu J (2021) Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China. Menopause 29(2):210–218

    Article  PubMed  Google Scholar 

  17. Pang KL, Low NY, Chin KY (2020) A review on the role of denosumab in fracture prevention. Drug Des Devel Ther 14:4029–4051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66(12):1139–1146

    Article  CAS  PubMed  Google Scholar 

  19. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523

    Article  CAS  PubMed  Google Scholar 

  20. Chen J, Zhou L, Liu X, Wen X, Li H, Li W (2021) Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. Int J Clin Pharm 43(1):2–10

    Article  CAS  PubMed  Google Scholar 

  21. Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G, Cao X, Wang P (2014) Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol 7(5):2113–2122

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Gu HF, Gu LJ, Wu Y, Zhao XH, Zhang Q, Xu ZR, Yang YM (2015) Efficacy and safety of denosumab in postmenopausal women with osteoporosis: a meta-analysis. Medicine (Baltimore) 94(44):e1674

    Article  CAS  PubMed  Google Scholar 

  23. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163–3170

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.researchgate.net/publication/288802810_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_The_Quality_of_Nonrandomised_Studies_in_Meta-analyses. Accessed 17 June 2022

  26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed  PubMed Central  Google Scholar 

  27. Zullo AR, Lee Y, Lary C, Daiello LA, Kiel DP, Berry SD (2021) Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study. Osteoporos Int 32(3):565–573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC (2017) Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. J Bone Miner Res 32(3):611–617

    Article  CAS  PubMed  Google Scholar 

  29. D’Silva KM, Cromer SJ, Yu EW, Fischer M, Kim SC (2021) Risk of incident atrial fibrillation with zoledronic acid versus denosumab: a propensity score-matched cohort study. J Bone Miner Res 36(1):52–60

    Article  CAS  PubMed  Google Scholar 

  30. Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27(9):2835–2844

    Article  CAS  PubMed  Google Scholar 

  31. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880

    Article  CAS  PubMed  Google Scholar 

  32. Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A (2018) Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125(6):547–551

    Article  PubMed  Google Scholar 

  33. Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M, Psachoulia E, Schmid T (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27(10):2967–2978

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99(7):2599–2607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Xijing Hospital, Air Force Military Medical University, 127 Changle Western Road, Xi’an, 710032, Shaanxi Province, China

    Weiwei Li, Zeqiong Ning, Zhifu Yang, Tingting Fan, Minna Yao, Wei Zhang, Mingming Wang, Aidong Wen & Jingwen Wang

Authors
  1. Weiwei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zeqiong Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhifu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tingting Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Minna Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mingming Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aidong Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jingwen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weiwei Li.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, W., Ning, Z., Yang, Z. et al. Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. Arch Osteoporos 17, 84 (2022). https://doi.org/10.1007/s11657-022-01129-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11657-022-01129-2

Keywords

Search

Navigation